Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition

Gil Awada,Teofila Seremet,Karel Fostier,Hendrik Everaert,Bart Neyns

Blood Advances（2018）

引用 19|浏览27

暂无评分

摘要

Key Points Treatment with a BRAF and MEK inhibitor can achieve a sustained response in BRAF V600 -mutant Langerhans cell histiocytosis. Detection of plasma BRAF V600 -mutant circulating tumor DNA is a promising biomarker for monitoring disease activity in this entity.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要